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A B S T R A C T
Atrial natriuretic peptide (carperitide) is used to treat heart failure in Japan, while brain natriuretic
peptide (nesiritide) is employed in Europe/USA.
Patients undergoing cardiac surgery have a complex underlying pathologic state that features
increased levels of neurohumoral factors due to activation of the renin–angiotensin–aldosterone system
and/or increased sympathetic activity. We considered that perioperative administration of carperitide
could be beneﬁcial for cardiac surgery patients, and we have conducted clinical investigations of its use.
This article reviews the effects of natriuretic peptides in cardiac surgery patients based on our experience
and on previous reports about perioperative management with carperitide or nesiritide.
 2015 Published by Elsevier Ltd on behalf of Japanese College of Cardiology.Contents
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The natriuretic peptides include atrial natriuretic peptide (ANP),
brain natriuretic peptide (BNP), and C-type natriuretic peptide
(CNP). Two of these hormones are produced by the heart, with ANP
beingsecreted in response toatrial distentionandBNPmainlybeing
secreted in response to ventricular loading. CNP is a locally acting
hormone synthesized in various tissues, including bone, where it is
essential for endochondral bone growth. CNP is also a neuropeptide* Corresponding author at: The Department of Cardiovascular Surgery, Nihon
University School of Medicine, 30-1 Oyaguchi-kamimachi, Itabashi-ku, Tokyo 173-
8610, Japan. Tel.: +81 3 3972 8111; fax: +81 3 3955 9818.
E-mail address: asezai.med@gmail.com (A. Sezai).
http://dx.doi.org/10.1016/j.jjcc.2015.09.011
0914-5087/ 2015 Published by Elsevier Ltd on behalf of Japanese College of Cardiolofound in the central nervous system, and its expression by vascular
endothelial cells and monocyte/macrophages has been detected as
well [1–4]. ANP and BNP have natriuretic and vasodilatory effects,
as well as inhibiting aldosterone secretion, myocardial hypertro-
phy, myocardial ﬁbrosis, the neuroendocrine system, and inﬂam-
matory cytokines, resulting in a cardioprotective effect by
modulation of vascular tone, renal and endothelial functions, and
ventricular contractility [4]. Clinically, human ANP (hANP; carperi-
tide) is used to treat heart failure in Japan, while BNP (nesiritide) is
employed for this indication in Europe and the USA.
In Japan, carperitide is classiﬁed as a Class IIa treatment for
heart failure in the Guidelines for Treatment of Acute Heart Failure
published by The Japanese Circulation Society, based on available
evidence of its efﬁcacy [5–7] (http://www.j-circ.or.jp/guideline/
pdf/JCS2011_izumi_h.pdf#search=’JCS+2011’). The efﬁcacy ofgy.
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[8]. In contrast, a large-scale study of nesiritide in patients with
acute heart failure (ASCEND-HF trial) found no difference in the
rates of re-hospitalization and 30-day mortality rate between the
nesiritide-treated and placebo groups [9]. The following reasons
for these differing outcomes can be suggested. (1) Different
administration methods: In the ASCEND-HF trial, a bolus dose of
nesiritide was given to 38% of the subjects before continuous low-
dose infusion, while bolus administration of carperitide is not
performed in Japan. (2) Differences in themanagement of ischemic
heart disease: While catheter-based therapy is frequently used for
patients with ischemic heart disease and heart failure in Japan,
adequate catheter therapymay not have been provided for the 60%
of the patients with ischemic heart disease enrolled in the
ASCEND-HF trial. (3) Different medical systems: Most patients
with heart failure are not discharged from the hospital within
30 days of admission in Japan, while most patients with heart
failure would have been discharged within that time in the
ASCEND-HF trial because its primary endpoint was re-hospitali-
zation for heart failure or death within 30 days. Therefore, it is
possible that more favorable results would be obtained by using
nesiritide in a similar manner to carperitide.
Patients undergoing cardiac surgery have a complex underlying
pathologic state that features increased levels of neurohumoral
factors due to activation of the renin–angiotensin–aldosterone
system (RAAS) and/or increased sympathetic activity along with
ﬂuid retention. Catecholamines and loop diuretics are generally
employed in the perioperative management of these patients.
However, use of catecholamines and loop diuretics may be
associated with a worse prognosis because of tachyarrhythmia,
ischemia-reperfusion injury, RAAS activation, and deterioration of
renal function leading to renal impairment [10,11]. During cardiac
surgery, the activity of various neurohumoral factors (RAAS,
catecholamines, antidiuretic hormone, and the sympathetic
nervous system) is enhanced, the inﬂammatory response may
be enhanced, coagulation can be activated, and third-space ﬂuid
retention and endothelial dysfunction can be induced by
cardiopulmonary bypass. Such changes might have an adverse
inﬂuence on cardiac and renal functions. We considered that
perioperative administration of carperitide could be beneﬁcial for
this complicated pathophysiology associated with cardiac surgery,
and we have conducted clinical research on low-dose continuous
infusion of carperitide during cardiac surgery (NU-HIT trial) since
1997. At present, the number of hospitals that routinely use
carperitide during cardiac surgery is increasing in Japan. Mitaka
et al. reviewed 11 studies evaluating ANP and 4 studies evaluating
BNP in patients undergoing cardiac surgery or abdominal aortic
surgery. They concluded that infusion of either peptide increased
the urine output and the creatinine clearance or glomerular
ﬁltration rate, and also reduced use of diuretics and the serum
creatinine level [12].
This review of the effects of natriuretic peptides in patientswith
cardiac surgery is based on our experience and on previous reports
about use of carperitide or nesiritide for perioperative manage-
ment.
Material and methods
We searched PubMed for articles from February 1987 to March
2015 using the terms ‘‘carperitide’’ and ‘‘cardiac surgery,’’ ‘‘hANP’’
and ‘‘cardiac surgery,’’ ‘‘ANP’’ and ‘‘cardiac surgery,’’ and ‘‘nesiri-
tide’’ and ‘‘cardiac surgery.’’ As a result, 1271 articles were
extracted for ‘‘nesiritide’’ and ‘‘cardiac surgery,’’ 309 for ‘‘ANP’’ and
‘‘cardiac surgery,’’ 46 for ‘‘hANP’’ and ‘‘cardiac surgery,’’ and 22 for
‘‘carperitide’’ and ‘‘cardiac surgery.’’ Among these articles, we
searched for English language reports on prospective randomizedcontrolled trials performed in adult patients undergoing non-
transplant cardiac surgery and found 14 reports on the use of
carperitide and 7 reports on nesiritide. We reviewed the data in
these reports and also included our report on carperitide (Table 1).
Cardiac protection by natriuretic peptides in cardiac surgery
In the ﬁeld of cardiovascular medicine, it has been reported that
carperitide reduces the levels of angiotensin-II, aldosterone, and
endothelin-1 which accelerate myocardial ﬁbrosis, ameliorates LV
remodeling [13], decreases cardiac sympathetic nerve activity
while inhibiting LV remodeling [14], and prevents ventricular
arrhythmia and ischemia-reperfusion injury [15]. In a canine
model of ischemia-reperfusion injury, carperitide was shown to
inhibit the decrease of myocardial high-energy phosphates,
prevent reperfusion arrhythmia, and increase cyclic guanosine
monophosphate (cGMP), resulting in a cardioprotective effect [16].
In the ﬁeld of cardiac surgery, our pilot study showed that low-
dose intraoperative infusion of carperitide led to inhibition of the
RAAS, an increase in urine volume, a decrease in the furosemide
dose, and compensation for the adverse inﬂuence of cardiopulmo-
nary bypass (CPB) [17]. In patients with LV dysfunction undergoing
coronary artery bypass grafting (CABG), infusion of carperitide
increased urine volume, decreased the furosemide dose, reduced
cardiac death or cardiac events during long-term follow-up, and
improved both serum BNP and the LV ejection fraction at 1 year
after surgery. Thus, carperitide had a strong cardioprotective effect
not only in the acute phase, but also over the long term [18]. In
patients with acute coronary syndrome undergoing urgent CABG,
carperitide decreased postoperative ischemia-reperfusion injury
and prevented postoperative ventricular arrhythmia. At 1 month
after surgery, the LV end-diastolic pressure, LV end-diastolic
volume index, and the serum BNP level were signiﬁcantly lower in
the carperitide group. In addition, the risk factors for long-term
cardiac events were non-use of perioperative carperitide and non-
use of postoperative aldosterone blockers, suggesting that
suppression of the RAAS by carperitide in the acute phase and
by aldosterone blocker therapy over the long term had a strong
positive inﬂuence on the prognosis [19–21]. In our clinical studies
of carperitide, isosorbide dinitrate was also used by themajority of
the subjects, while PDE III inhibitors were administered to about
30% of the patients from both groups in the NU-HIT trial for LVD.
Thus, there was no difference in the use of isosorbide dinitrate or
PDE III inhibitors between the groups with andwithout carperitide
treatment in these studies. To evaluate the vasodilatory effect of
each agent, carperitide should be compared directly with
isosorbide dinitrate or a PDE III inhibitor and this has been done
in two studies so far. In patients with acute heart failure, nitrate
therapy signiﬁcantly reduced the diastolic pulmonary arterial
pressure and systemic vascular resistance index compared with
carperitide, but there were no differences in clinical outcomes
[22]. In the other study, carperitide signiﬁcantly improved EF,
LVEDVI, and LVESVI compared with nitroglycerin in AMI patients,
indicating suppression of LV remodeling by carperitide [13]. How-
ever, further investigation is necessary because these effects of
carperitide have not fully been examined and no studies have
compared carperitidewith PDE III inhibitors. In our clinical studies,
treatment with carperitide also signiﬁcantly reduced the use of
furosemide because of its diuretic effect.
The good long-term results obtained after perioperative
administration of carperitide for several days were consistent
with the ﬁndings of the J-WIND study and the mechanisms
involved are probably also similar [8]. It is probable that
carperitide has a ‘‘legacy effect’’, i.e. prevention of LV remodeling
in the acute phase by inhibition of the RAAS, particularly
aldosterone, leads to a better long-term outcome. Another possible
Table 1
Randomized clinical trials of natriuretic peptides during cardiac surgery.
Author Natriuretic
peptide




Duration Superiority of carperitide and nesiritide versus placebo
Perioperative results Long-term results (>6 months)
Sezai (2000) [17] ANP CABG 40 0.03 or 0.05 24h c-GMP, RAAS, UV, U-Na,
respiratory index, reduction
in the use of furosemide
–
Hayashida (2000) [38] ANP Mitral valve surgery 18 0.05 6h c-GMP, UV, FENa –




Hayashi (2004) [41] ANP Mitral valve surgery 26 0.05 24h Renin, ALD –
Swa¨rd K (2004) [37] ANP AKI after cardiac
surgery
61 0.05 ANP: 5.3 0.8 days
Placebo: 4.3 0.7 days
Dialysis-free, CCr –
Sezai (2007) [21] ANP CABG for ACS 124 0.02 – Postoperative arrhythmias,
CK-MB, lactate, sCr, f
reduction in the use of
furosemide, resp. time,
ICU and hospital stay
Cardiac events (2 years), BNP
(1 year), LVEDP (1 month)
Mentzer (2007) [28] BNP CABG with LVD 279 0.01 39.421.6h UV, sCr, respiratory failure,
hospital stay
180-day mortality
Chen (2007) [43] BNP CVS with CKD 40 0.005 24h cGMP, cystatin, ALD –
Izumi (2008) [39] ANP CABG and valve surgery
with CKD
18 0.01 or 0.02 5.2 0.6 days UV, U-NAG, sCr –
Dyke (2008) [44] BNP Cardiac surgery with
LVD and CKD
266 0.01 24–96h eGFR, postoperative renal
function, sCr
–
Beaver (2008) [46] BNP Maze+mitral valve
surgery
19 0.01 72h PaO2/FiO2 –
Sezai (2009) [30] CABG with non-CKD 504 0.02 2.23 0.82 days UV, postoperative
complications, hospital stay,
sCr, RFI, RAAS, ICU and
hospital stay
–
Ejaz (2009) [45] BNP High-risk cardiac
surgery
94 0.01 5 days Postoperative AKI, sCr,
hospital stay
–
Sezai (2010) [18] ANP CABG with LVD 133 0.02 2.81.1 days Reduction in the use of
furosemide and potassium,




Cardiac death and cardiac
events (12 years), BNP (1 year)
Sezai (2011) [32] ANP CABG with CKD 285 0.02 2.981.93 days cGMP, reduction in the use
of furosemide, hospital stay, sCr
Dialysis-free rate (1 year)
Cardiac events (1 year)
Hisatomi (2012) [42] ANP CVS using CPB 70 0.0350.0037 6.23.7 days sCr, reduction in the use of furosemide –
Sezai (2013) [57] ANP High-risk CABG 367 0.02 – Hospital stay, sCr MACCE-free and dialysis-free
rate (2 years), sCr (1 year), BNP
(1 year)
Mori (2014) [49] ANP Aortic arch surgery 42 0.0125 24h UV, postoperative AKI –
Chen (2014) [47] BNP PH after MVR 60 2mg/kg (bolus) +0.01 12h PAP, PCWP, PVRI –
Shibasak (2015) [48] ANP Cardiac surgery 30 0.025 24h Albumin, UV, interleukin-6, renin –
ACS, acute coronary syndrome; AKI, acute kidney injury; ALD, aldosterone; Ang-II, angiotensin-II; ANP, atrial natriuretic peptide (carperitide); BNP: brain natriuretic peptide (nesiritide); CABG, coronary artery bypass grafting;
CCr, creatinine clearance; c-GMP, cyclic-guanosine monophosphate; CKD, chronic kidney disease; CK-MB, creatine kinase MB; CVS, cardiovascular surgery; eGFR, estimated Glomerular ﬁltration rate; FENa, fractional sodium
excretion; ICU, intensive care unit; LVEDP, left ventricular end-diastolic pressure; LVD, left ventricular dysfunction; major adverse cardiac and cerebrovascular event; P, placebo; PH, pulmonary hypertension; PVC, premature
ventricular contraction; RAAS, renin–angiotensin–aldosterone system; RFI, renal failure index; sCr, serum; U-Na, urinary sodium; U-NAG, urinary N-acetyl-beta-D-glucosaminidase; UV, urine volume; VT, ventricular
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While patients with heart disease have a risk of developing cardiac
events during long-term follow-up, renal events are also common,
and it is possible that protection of the kidneys by carperitide in the
acute phase decreases renal events over the long term.
We developed a procedure for administering cardioplegia
combined with carperitide (hANP shot: administration of 100 mg
of carperitide into the ascending aorta during infusion of
cardioplegia), and our investigations demonstrated that carperi-
tide had a cardioprotective effect by maintaining myocardial ATP
levels and inhibiting intracellular Ca overload during reperfusion,
with electron microscopy revealing improved integrity of the
mitochondria and myocardial ﬁbers in the carperitide group [23–
25]. A clinical trial of hANP shot conﬁrmed its safety because no
serious adverse events occurred and showed that the cardiopro-
tective effect of carperitide was mediated via cGMP (a second
messenger of carperitide), while inhibition of ischemia-reperfu-
sion injury was revealed by measurement of biomarkers along
with a decrease in postoperative arrhythmias [26]. Thus, hANP
shot shows promise as a new cardioprotective technique for
cardiac surgery. In this context, Tsuneyoshi et al. performed LV
repair in a rat model of LV aneurysm and reported that intravenous
carperitide had beneﬁcial effects on postoperative LV remodeling,
LV function, and ﬁbrosis, suggesting that carperitide infusion could
be useful after LV surgery [27].
With regard to nesiritide, Mentzer et al. reported that nesiritide
treatment achieved a shorter hospital stay and lower 180-day
mortality rate in patients with LV dysfunction undergoing CABG
(NAPA trial) [28]. Lazar et al. performed a study of bolus and
continuous nesiritide administrationwith cardioplegia in a porcine
model, and they reported signiﬁcantly smaller infarcts, better
preservation of endothelial function, and less pulmonary edema in
the animals receiving nesiritide [29]. Although there are only a few
reports about good results with nesiritide in cardiac failure, it
might be expected to improve the prognosis after cardiac surgery.
Renal protection by natriuretic peptides in cardiac surgery
In our trial of 504 patients without renal impairment who
underwent CABG, the maximum postoperative serum creatinine
(Cr) level and percent increase of Cr were signiﬁcantly lower in the
carperitide group. Four patients in the placebo group required
hemodialysis versus none in the carperitide group, and the
carperitide group showed lower fractional sodium excretion, a
potent natriuretic action of carperitide, and inhibition of the RAAS,
[(Fig._1)TD$FIG]Fig. 1. (Left panel) Hemodialysis-free rate in patients with chronic kidney disease (CKD).
rate in the high-risk group (EuroSCORE6). The hemodialysis-free rate andMACCE-free rwhich prevented the deterioration of postoperative renal function
[30,31]. In a randomized controlled trial of 303 patients with
chronic kidney disease (CKD) who underwent CABG, the dialysis-
free rate at 1 year postoperatively was 98.6% in the carperitide
group versus 91.6% in the placebo group (being signiﬁcantly higher
in the carperitide group), and postoperative Cr was signiﬁcantly
lower in the carperitide group not only in the acute stage but also
at 1 year [32]. Intravenous administration of carperitide to patients
with CKD not only improved perioperative renal function, but also
prevented the progression of CKD [33]. In this study, the
postoperative dialysis-free rates for the carperitide and placebo
groups were 99.3% and 91.6% at 1 year, 97.8% and 90.1% at 5 years,
and 97.8% and 81.1% at 10 years, respectively, and these rates were
signiﬁcantly higher in the carperitide group (p = 0.0014) (Fig. 1). In
dialysis patients, non-use of carperitidewas a signiﬁcant risk factor
for early death and major adverse cardiovascular and cerebrovas-
cular events (MACCE). No studies on the efﬁcacy of carperitide in
dialysis patients have been reported. While the renoprotective
effect of carperitide has no meaning for dialysis patients, this
research suggests the possibility of preventing the onset of MACCE
not only in the early postoperative period but also over the long
term by its cardioprotective effect [34]. In our clinical studies, the
diuretic effect of carperitide led to a signiﬁcant reduction in the use
of furosemide, while furosemide may have had adverse effects on
renal function via mechanisms such as RAAS activation in the
group without carperitide.
Various effects of carperitide on the kidneys have been
reported, and it is considered to act directly on the renal tubules
(exhibiting a diuretic effect) to increase urinary sodium excretion,
thereby maintaining the electrolyte balance and avoiding renal
parenchymal damage caused by high-dose diuretics [35]. Valsson
et al. administered carperitide for 30 min to patients with acute
renal failure and heart failure after cardiac surgery, and found that
the urine volume, glomerular ﬁltration rate, and renal blood ﬂow
increased by 62%, 43%, and 38%, respectively, whereas renal
vascular resistance decreased by 30% [36]. Their group also
conducted a randomized clinical trial (RCT) in 61 patients with
combined acute renal failure and heart failure after cardiac
surgery, revealing that the requirement for hemodialysis was
decreased by carperitide and dialysis-free survival was improved
[37]. Hayashida and colleagues reported that their carperitide
group had a signiﬁcantly higher urine volume than the placebo
group, as well as better hemodynamics and water balance
[38]. Izumi investigated patients with CKD undergoing cardiac
surgery, and reported a signiﬁcant postoperative decrease of Cr, a(Right panel) Major adverse cardiovascular and cerebrovascular event (MACCE)-free
atewere both signiﬁcantly higher in the carperitide group than in the placebo group.
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increase in the urinary N-acetyl-beta-D-glucosaminidase level in
the carperitide group [39]. Hayashi et al. reported signiﬁcantly
lower total doses of furosemide and potassium chloride during the
ﬁrst 72 h after surgery in the carperitide group. On the ﬁrst
postoperative day, plasma renin activity and the plasma aldoste-
rone level were also signiﬁcantly lower in the carperitide group
[40,41]. Hisatomi et al. performed a multicenter trial of carperitide
in 88 patients with CKD undergoing cardiovascular surgery,
reporting that postoperative Cr was signiﬁcantly lower and
creatinine clearance was signiﬁcantly higher in the carperitide
group than in the controls. One patient in the control group
required hemodiaﬁltration, but no patient from the carperitide
group required it [42].
In an investigation of nesiritide for patients with CKD
undergoing cardiac surgery (NAPA trial), the plasma levels of
cystatin and aldosterone, serum Cr, and estimated Ccr were all
better in the nesiritide group [43]. Dyke et al. performed a
subanalysis of this trial and reported that postoperative renal
dysfunction was less frequent in the nesiritide group, particularly
moderate or severe renal dysfunction [44].
Ejaz et al. reported that nesiritide did not reduce the incidence
of dialysis and/or all-cause mortality. However, fewer patients
receiving nesiritide had acute kidney injury compared with
controls (2.2% versus 22.4%), and mean Cr was lower during the
immediate postoperative period for patients undergoing high-risk
cardiac surgery in the nesiritide group [45]. Beaver et al. studied
19 patients undergoing the maze procedure and mitral valve
surgery, and reported that there were no differences in urine
volume, PaO2/FiO2, endothelin-1, and sCr between those receiving
placebo or nesiritide [46].
Pulmonary protection by natriuretic peptides in cardiac surgery
patients
There have only been a few investigations into the effect of
natriuretic peptides on the pulmonary circulation. Among them,
Chen et al. performed an RCT that compared nesiritide, prosta-
glandin E1 (PGE1), and placebo in patients with pulmonary
hypertension after mitral valve replacement. While they reported
that both nesiritide and PGE1 improved pulmonary hypertension,
the effect of nesiritide was slower and weaker than that of PGE1,
suggesting that these two agents act on pulmonary arterial
pressure via different pathways [47]. Shibasaki et al. found no
difference in the pulmonary blood volume index, extravascular
lung water index, and pulmonary vascular permeability index
between the patients treatedwith carperitide or placebo, but urine
volumewas signiﬁcantly higher and the interleukin-6 and albumin
levels were signiﬁcantly lower in the carperitide group. Accord-
ingly, Shibasaki et al. concluded that carperitide reduces third-
space ﬂuid retention caused by CPB [48].
Other effects of natriuretic peptides
Thoracic aortic surgery
The only RCT on use of natriuretic peptides during thoracic
aortic surgery was reported by Mori et al., who administered
carperitide or placebo for 24 h from the induction of anesthesia in
patients undergoing elective aortic arch surgery. They reported that
intraoperative urine output was signiﬁcantly higher in the carperi-
tide group, while the incidence of postoperative acute kidney injury
was 73% in the placebo group versus 30% in the carperitide group,
being signiﬁcantly lower in the carperitide group [49].
We conducted a retrospective investigation in patients
undergoing surgery for thoracic aortic aneurysm using hypother-
mia and selective cerebral perfusion, which is the most stressful ofthe procedures employing CPB. The urine volume during CPB and
that fromweaning off CPB until the return to the intensive care unit
was signiﬁcantly larger in the carperitide group, while blood loss,
blood transfusion volume, furosemide dose, and KCl dose were all
signiﬁcantly lower in the carperitide group. The peak lactate level
was also signiﬁcantly lower in the carperitide group, and these
ﬁndings indicated that carperitide inhibited ischemia/reperfusion
injury [50].
In a patient with acute aortic dissection complicated by the
myonephropathic metabolic syndrome (MNMS), high-dose
(0.1mg/kg/min) carperitide improved postoperative MNMS with-
out the need for hemodialysis. Although carperitide was originally
investigated for heart failure, it has various pharmacologic effects,
and MNMS may have been alleviated through a strong diuretic
effect and prevention of ischemia/reperfusion injury [51]. Based on
our experience with carperitide, a low infusion rate of 0.02 mg/kg/
min is generally sufﬁcient. At high doses, the risk of low blood
pressure may outweigh the beneﬁts of carperitide infusion.
However, further investigation is necessary to ﬁnd the optimal
infusion rate for each condition, because infusion at a high rate of
0.1 mg/kg/min is beneﬁcial for some patients, e.g. for improvement
of reperfusion injury associated with MNMS as described above.
Postoperative atrial ﬁbrillation
Postoperative atrial ﬁbrillation (POAF) is the most common
complication after cardiac surgery, with an incidence of 16–85%
[52,53]. For prevention of this complication, amiodarone and beta-
blockers are recommended [54,55]. In the NU-HIT study of LV
dysfunction, carperitide was shown to reduce the incidence of
POAF [18]. Among 668 patients undergoing CABG, POAF occurred
in 41/335 patients (12.2%) from the carperitide group versus 110/
333 patients (32.7%) from the placebo group (p < 0.0001). The
mechanisms by which carperitide protects against POAF may
include (1) RAAS inhibition, (2) an anti-ischemic effect, and (3)
improvement in volume overload via its diuretic effect [56]. Since
an anti-arrhythmic effect or suppression of atrial ﬁbrillation by
natriuretic peptides has not been reported previously, further
investigation is needed.
High-risk patients
In 367 high-risk patients (total EuroSCORE 6 points) from the
NU-HIT trial, the postoperative MACCE-free rate was signiﬁcantly
higher in the carperitide group than the placebo group, being 95.2%
versus 79.6% at 1 year, 87.2% versus 71.7% at 5 years, and 86.1%
versus 63.3% at 10 years (p < 0.0001) (Fig. 1). None of the patients
from the carperitide group started hemodialysis after surgery
versus 7 patients in the placebo group, and the dialysis rate was
signiﬁcantly lower in the carperitide group (p = 0.0147). MACCE
was strongly associated with an age75 years, CKD, hemodialysis,
LV dysfunction, and non-use of carperitide [57] (Fig. 1).
Because we have demonstrated that carperitide inhibits RAAS
activity, we consider that it is indicated for cardiac surgery using
CPB. In addition, carperitide shows a stronger effect in high-risk
patients, as noted above, and is not only beneﬁcial in the acute
perioperative phase but also over the long term.
Conclusion
Carperitide is already regarded as ﬁrst-line therapy for heart
failure in Japan, and it is also considered to be appropriate for use
during cardiac surgery associated with neurohumoral activation
based on the characteristics of this drug demonstrated by domestic
clinical research. Similar to carperitide, nesiritide has been
reported to achieve good long-term results in cardiac surgery
patients, suggesting that natriuretic peptide therapy could be an
important aspect of perioperative management due to its possible
A. Sezai, M. Shiono / Journal of Cardiology 67 (2016) 15–2120cardioprotective and renoprotective effects, as well as compensat-
ing for CPB, preventing left ventricular remodeling, arrhythmias,
and ischemia-reperfusion injury, and protecting major organs
including the kidneys.
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